Développement de la spectrométrie rétinienne pour l'identification de nouveaux biomarqueurs précoces de la maladie de Parkinson

帕金森病新生物标志物鉴定光谱研究的开发

• 批准号: 538422-2018
• 负责人: Parent, Martin
• 金额: $ 3.01万
• 依托单位: Université Laval
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=688411
• 关键词: veloppement; de; la; spectrom; trie

The regulation of retinal blood flow and oxygenation are recognized as root causes of the majority of ocular diseases, such as glaucoma. There is thus a huge interest in measuring these parameters in vivo, ideally using non-invasive methods. Retnia's technology, based on optical spectroscopy, enables such non-invasive measurements in laboratory and clinical settings. Recently, there has been growing evidence that many neurodegenerative diseases also have an effect on the retina, which is part of the central nervous system. Of the many neurodegenerative diseases that could possibly be sensed in the eye, Parkinson's disease (PD) stands out, due to the retina's similarities to the substantia nigra, a midbrain region that is known to degenerate in PD. PD affects more than 100 000 Canadians and is considered as the second most common neurodegenerative disease. Some disease-modifying treatments exist but drugs that have been tested have provided disappointing results. This can be largely explained by the fact that the cardinal symptoms of PD typically manifest only when more than half of dopaminergic neurons in the substantia nigra are lost. Therefore, early biomarkers of PD are urgently needed to succeed in disease-modifying therapies. In the proposed research project, we will use Retnia's multimodal imaging device to perform spectroscopy on the retina of healthy and parkinsonian monkeys in order to identify and locate optical biomarkers in the form of hemoglobin and melanin retinal content and abnormalities, for early detection of PD.

视网膜血流和氧合的调节被认为是大多数眼部疾病（例如青光眼）的根本原因。因此，人们对体内测量这些参数非常感兴趣，最好使用非侵入性方法。 Retnia 的技术基于光谱学，可在实验室和临床环境中实现此类非侵入性测量。最近，越来越多的证据表明，许多神经退行性疾病也会对视网膜（中枢神经系统的一部分）产生影响。在眼睛可能感觉到的许多神经退行性疾病中，帕金森病 (PD) 脱颖而出，因为视网膜与黑质相似，黑质是已知在帕金森病中会退化的中脑区域。 PD 影响超过 10 万加拿大人，被认为是第二常见的神经退行性疾病。存在一些缓解疾病的疗法，但经过测试的药物却提供了令人失望的结果。这在很大程度上可以通过以下事实来解释：帕金森病的主要症状通常只有在黑质中超过一半的多巴胺能神经元丢失时才会出现。因此，迫切需要 PD 的早期生物标志物才能在疾病缓解疗法中取得成功。在拟议的研究项目中，我们将使用Retnia的多模态成像设备对健康和帕金森猴的视网膜进行光谱分析，以识别和定位血红蛋白和黑色素视网膜含量和异常形式的光学生物标志物，从而早期检测帕金森病。